ARCHIVES

Six-Year Follow Up Of Phase III Sprycel Trial Demonstrates 71 Percent Overall Survival

This article is from The Cancer Letter archive.

Vol. 35 No. 7 | July 27, 2012

Download PDF Visit The Full Archive

Related Articles

Congress Holds Recision Hearings

February 28, 1975

GAO Probes NCI Intramural Program, Finds All Is Well, But Won’t Report It

October 22, 1982

National Cancer Policy Board calls for public-private partnership for R&D in pediatric cancer drugs.

April 22, 2005

Jane Henney Said Tentative Choice For FDA Commissioner

May 22, 1998

In Brief: McIntyre New AACI President, Salmon President Elect; Hubbard NCI AD; Underleider CIB Chief

September 30, 1988

Funding Opportunities

April 26, 2002